DIG
ATYR

Dauntless Investment Group’s aTyr Pharma ATYR Stock Holding History

Dauntless Investment Group’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,000
Closed -$11K – 95
2025
Q4 		$11K Hold
14,000
– – 0.01% 59
2025
Q3 		$10.1K Buy
+14,000
New +$63.4K 0.01% 64

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dauntless Investment Group's ATYR Position: Q3 2025 in Review

Dauntless Investment Group sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 158,402 shares — an estimated $718K sold.

Dauntless Investment Group first reported a position in ATYR in Q1 2025 and held it in 2 quarters. The position peaked at $803K in Q2 2025. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.

  • Dauntless Investment Group reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
  • Dauntless Investment Group sold 158,402 aTyr Pharma shares in Q3 2025, an estimated $718K.
  • Dauntless Investment Group first reported a position in aTyr Pharma in Q1 2025 and held it in 2 quarters.
  • Dauntless Investment Group's aTyr Pharma position peaked at $803K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.

Based on Dauntless Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.